SCHEMBL5469148

SCHEMBL5469148

CC1Cc2ccccc2N1S(=O)(=O)c1ccc(Cl)c(N)c1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.63
▸ ALDH1A1 P00352 5/20 0.63
▸ L3MBTL1 Q9Y468 2/20 0.63
▸ TDP1 Q9NUW8 1/20 0.63
▸ NPSR1 Q6W5P4 2/20 0.58
▸ KMT2A Q03164 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ MAPT P10636 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ CACNA1H O95180 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ MAPK1 P28482 1/20 0.48
▸ TSHR P16473 2/20 0.48
▸ CRHBP P24387 1/20 0.48
▸ CRHR2 Q13324 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ ESR1 P03372 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469042 0.88 ESR1 (0.63) LMNAALDH1A1L3MBTL1TDP1NPSR1
SCHEMBL5474116 0.82 ALDH1A1 (0.59) LMNAALDH1A1L3MBTL1TDP1NPSR1
SCHEMBL2693466 0.79 LMNA (0.81) LMNAALDH1A1L3MBTL1TDP1NPSR1
SCHEMBL8421007 0.78 LMNA (1.00) LMNAALDH1A1L3MBTL1TDP1NPSR1
SCHEMBL2692953 0.77 LMNA (0.77) LMNAALDH1A1L3MBTL1TDP1NPSR1
SCHEMBL2692768 0.74 ALDH1A1 (0.75) LMNAALDH1A1L3MBTL1TDP1NPSR1
SCHEMBL5461646 0.74 L3MBTL1 (0.50) LMNAALDH1A1L3MBTL1TDP1NPSR1
SCHEMBL3004722 0.74 ESR1 (0.63) LMNAALDH1A1L3MBTL1TDP1NPSR1
SCHEMBL23185390 0.73 LMNA (0.71) LMNAALDH1A1L3MBTL1TDP1NPSR1
SCHEMBL18131015 0.73 LMNA (0.71) LMNAALDH1A1L3MBTL1TDP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010537-A1 Fused pyramidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-11 — — US disclosed
US-20070010537-A1 Fused pyramidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-11 — — US disclosed
US-20070010537-A1 Fused pyramidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-11 — — US disclosed
EP-1657238-A1 FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010537-A1 Fused pyramidine derivative and use thereof NR5A1, GNRHR, RXFP3 LMNA 2632/4885ALDH1A1 1875/4885L3MBTL1 1747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback